ArticleAMB Express2026
Eicosadienoic acid enhances antibody production in CHO cells by prolonging culture longevity and attenuating apoptosis.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fatty acids are key nutrients exerting multiple functions in cells. This study aimed to investigate the effect of fatty acids on antibody expression in Chinese hamster ovary (CHO) cells. Among different fatty acids, cis, cis − 11, 14-eicosadienoic acid (EDA, C20:2, Δ11,14-cis) was screened to exert the strongest effect to boost antibody yield in CHO-IgG cells tested. In batch and fed-batch culture processes, the antibody yield was promoted by 48% and 59% with supplementation of 10 µM of EDA respectively. Meanwhile, the culture duration was significantly prolonged while the apoptosis ratios were suppressed by EDA. The addition of EDA also promoted the yield of other antibodies transiently expressed in CHO-K1 cells, including Rituximab, Herceptin, and one anti-uPAR antibody. These findings revealed the potential of EDA in promoting antibody expression in CHO cells, shedding light on the application of functional fatty acids in therapeutic antibody manufacturing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.